Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

The Addition of Ibritumomab Tiuxetan (IT) to the ATG/TLI Preparative Regimen Is Safe and May Enhance Post-Transplant Response and Outcomes for Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Michael Low Cardenas, MD, Mehrdad Abedi, MD, Christina Romo, Carol M. Richman, MD, Megan Daly, MD, Joseph Tuscano, MD

Blood (2019) 134 (Supplement_1): 3334.

https://doi.org/10.1182/blood-2019-130870

Published: 2019

Journal Articles

Health Care Utilization in Transplanted Versus Non-Transplanted Sickle Cell Disease Patients

Santosh L. Saraf, MD, Krishna Ghimire, MD, Pritesh Patel, MD, Karen Sweiss, PharmD, John G. Quigley, Irum Khan, MBBS, David Peace, MD, Michel Gowhari, DO, Shivi Jain, MD, John P. Galvin, MDMS,MPH, Robert E. Molokie, MD, Victor R. Gordeuk, MD, Damiano Rondelli, MD

Blood (2018) 132 (Supplement 1): 313.

https://doi.org/10.1182/blood-2018-99-113666

Published: 2018

Journal Articles

To Evaluate the Inhibition Leukemia Cell Effect of Haploidentical Spleen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation

Weihong Chen, MD, Mei Xie

Blood (2017) 130 (Supplement 1): 5491.

https://doi.org/10.1182/blood.V130.Suppl_1.5491.5491

Published: 2017

Journal Articles

Bortezomib Consolidation after Nonmyeloablative Allogeneic Stem Cell Transplantation Leads to a High Incidence of Immunophenotypic Complete Response in Young and/or High-Risk Multiple Myeloma Patients

Richard LeBlanc, MD, Imran Ahmad, MD, Rafik Terra, PhD, Séverine Landais, PhD, Michael Sebag, MD PhD, Emilie Lemieux-Blanchard, MD, Nadia M. Bambace, MD, Lea Bernard, MD, Sandra Cohen, MD, Jean-Sebastien Delisle, MD PhD, Thomas Kiss, MD, Silvy Lachance, MD, Denis-Claude Roy, MD, Guy Sauvageau, MD PhD, Jean Roy, MD

Blood (2016) 128 (22): 2306.

https://doi.org/10.1182/blood.V128.22.2306.2306

Published: 2016

Journal Articles

Assessment of Erythroid Chimerism in Sickle Cell Patients Undergoing HSCT By Digital Droplet PCR

Lihui Yin, PhD, Rupa A Udani, PhD, Mary Parlow, Daniel B Bellissimo, PhD, Joel A Brochstein, MD FAAP

Blood (2014) 124 (21): 563.

https://doi.org/10.1182/blood.V124.21.563.563

Published: 2014

Journal Articles

Assessment Of The Endocrine Function Of Patients With Sickle Cell Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Helen Gharwan, MD, DSc, Courtney Fitzhugh, MD, Mary Link, RN, Wynona Coles, RRT, Deborah Citrin, MD, John F. Tisdale, MD, Matthew M. Hsieh, MD

Blood (2013) 122 (21): 4646.

https://doi.org/10.1182/blood.V122.21.4646.4646

Published: 2013

Journal Articles

Thalidomide, Lenalidomide and Pomalidomide Disrupt Epstein-Barr Virus (EBV) Latency: Clinical Implications

Richard Julian Jones, Ph.D., Shannon C. Kenney, MD, Christopher Dawson, PhD, Robert Z. Orlowski, M.D., Ph.D.

Blood (2013) 122 (21): 3499.

https://doi.org/10.1182/blood.V122.21.3499.3499

Published: 2013

Journal Articles

Whole Genome Sequencing On Donor Cell Leukemia in a Patient with Multiple Myeloma Identified Gene Mutations That May Provide Insights to Leukemogenesis.

Eric S.K. Ho, MPhil, Howard C.H. Chow, MPhil, Chris T.L. Chan, PhD, Ruibang Luo, BE, Henry C.M. Leung, PhD, Siu Ming Yiu, PhD, Francis Y.L. Chin, PhD, Yok Lam Kwong, MD, Anskar Y.H. Leung, MD

Blood (2012) 120 (21): 2414.

https://doi.org/10.1182/blood.V120.21.2414.2414

Published: 2012

Journal Articles

Improved Clinical Outcomes in Chronic Lymphocytic Leukemia Patients with 17p Deletion (CLL 17p-) Who Are Able to Proceed with a Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) Following an Initial Consultation with the Transplant Service: A Single Centre Experience

LM Poon, Patricia S Fox, MS, Barry I. Samuels, MD, Susan O'Brien, M.D., Alessandra Ferrajoli, M.D., Michael J. Keating, MD, Elias J. Jabbour, MD, Yvonne Hsu, Lynne V. Abruzzo, MD, PhD, Richard E. Champlin, Roland Bassett, Issa F. Khouri, MD

Blood (2012) 120 (21): 1977.

https://doi.org/10.1182/blood.V120.21.1977.1977

Published: 2012

Journal Articles

Bortezomib and BEAM-Rituximab Reduced-Intensity Conditioning for High-Risk Lymphoma Patients Who Are Not Eligible for Nonmyeloablative Allogeneic Stem Cell Transplantation

Issa F. Khouri, MD, Saliba M. Rima, MD, Francesco Turturro, MD, Martin Korbling, MD, Celina Ledesma, Gabriela Rondon, MD, Amin M. Alousi, M.D., Paolo Anderlini, MD, Qaiser Bashir, MD, Stefan O. Ciurea, Chitra M. Hosing, M.D., Uday R. Popat, M.D., Yasmeen Charafeddine, Yasuhiro Oki, MD, Luis E Fayad, MD, Richard E. Champlin

Blood (2012) 120 (21): 4157.

https://doi.org/10.1182/blood.V120.21.4157.4157

Published: 2012

Journal Articles

Nonmyeloablative allogeneic transplantation with or without 90 yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results

Blood (2012) 119 (26): 6373–6378.

https://doi.org/10.1182/blood-2012-03-417808

Published: 2012

Journal Articles

Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) for Patients with Severe Sickle Cell Disease (SCD)

Matthew M Hsieh, Courtney D Fitzhugh, MD, R. Patrick Weitzel, PhD, Wynona Coles, M Beth Link, John F. Tisdale

Blood (2011) 118 (21): 10.

https://doi.org/10.1182/blood.V118.21.10.10

Published: 2011

Journal Articles

Alemtuzumab Use and Survival After Reduced Intensity Allogeneic Stem Cell Transplantation in High-Risk Chronic Lymphocytic Leukemia (CLL),

Wei Ding, MD, PhD, Tait D. Shanafelt, MD, Kari Rabe, MS, Timothy G. Call, MD, Clive S. Zent, MD, Neil Kay, MD, David James Inwards, MD, Deborah Bowen, Mark R. Litzow, MD, Susan L Slager, PhD, Susan Schwager, William J Hogan, MBBCh

Blood (2011) 118 (21): 4152.

https://doi.org/10.1182/blood.V118.21.4152.4152

Published: 2011

Journal Articles

Nonmyeloablative Allogeneic Stem Cell Transplantation with/ or without 90 yttrium Ibritumomab Tiuxetan ( 90 YIT) Is Curative for Relapsed Follicular Lymphoma: Median 9 Year Follow-up Results

Blood (2011) 118 (21): 662.

https://doi.org/10.1182/blood.V118.21.662.662

Published: 2011

Journal Articles

Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial

Evelien Kneppers, Bronno van der Holt, Marie-Jose Kersten, Sonja Zweegman, Ellen Meijer, Gerwin Huls, Jan J. Cornelissen, Jeroen J. Janssen, Cynthia Huisman, Petra B. Cornelisse, Cheryl P. Bruijnen, Maarten Emmelot, Pieter Sonneveld, Henk M. Lokhorst, Tuna Mutis, Monique C. Minnema

Blood (2011) 118 (9): 2413–2419.

https://doi.org/10.1182/blood-2011-04-348292

Published: 2011

Journal Articles

Outcome In Follicular Lymphoma (FL) Patients (pts) Relapsing After Autologous Stem Cell Transplantation (ASCT): Allografting Vs. Conventional Therapy

Grace-Julia Okoroji, Leandro de Padua Silva, Rima M Saliba, Martin Korbling, McLaughlin Peter, Chitra Hosing, Paolo Anderlini, Amin Alousi, Marcos de Lima, Partow Kebriaei, Uday Popat, Muzaffar Qazilbash, Luis Fayad, Felipe Samaniego, MD, MPH, Nathan Fowler, Richard Champlin, Fredrick Hagemeister, Issa F Khouri

Blood (2010) 116 (21): 3510.

https://doi.org/10.1182/blood.V116.21.3510.3510

Published: 2010

Journal Articles

Treatment of Older Patients, 40 to 70 Years of Age, with Acute Lymphoblastic Leukemia According to a Chemotherapy Regimen That Includes a Novel Pre-Phase for Rapid Tumor Load Reduction. Results of the Dutch-Belgian HOVON-71 Study.

Simon M. G. J. Daenen, Bronno van der Holt, Adriaan W. Dekker, Roelof Willemze, Anita Rijneveld, Bart J. Biemond, Petra Muus, Arjan A van de Loosdrecht, Harry Schouten, M. van Marwijk Kooy, Dimitri Breems, Johan Maertens, Hilde Demuynck, Pierre W Wijermans, Shulamiet Wittebol, Ellen W. de Klerk, Jan J. Cornelissen

Blood (2009) 114 (22): 2028.

https://doi.org/10.1182/blood.V114.22.2028.2028

Published: 2009

Journal Articles

Bendamustine Is Highly Active in Heavily Pre-Treated Relapsed and Refractory Hodgkin Lymphoma and Serves as a Bridge to Allogeneic Stem Cell Transplant.

Alison J. Moskowitz, MD, Paul A. Hamlin, Jr., MD, John Gerecitano, MD, PhD, Steven M. Horwitz, MD, Matthew Matasar, MD, Jessica Meikle, Ariela Noy, MD, Maria Lia Palomba, MD, Carol S. Portlock, MD, David J. Straus, MD, Jill M Vanak, ACNP, Andrew D. Zelenetz, MD, PhD, Craig H Moskowitz, MD

Blood (2009) 114 (22): 720.

https://doi.org/10.1182/blood.V114.22.720.720

Published: 2009

Journal Articles

Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NMHCT) for Patients Relapsing after Autologous Stem Cell Transplantation (autoHCT) for B Cell Non-Hodgkin Lymphoma (NHL)

Cesar O Freytes, MD, Jeanette Carreras, MPH, Mei-Jie Zhang, PhD, Ginna G. Laport, MD, Koen Van Besien, MD, Hillard M. Lazarus, MD, Parameswaran Hari, MD, MS

Blood (2008) 112 (11): 459.

https://doi.org/10.1182/blood.V112.11.459.459

Published: 2008

Journal Articles

Prognostic Factors for Outcome of Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) in Poor-Risk Chronic Lymphocytic Leukemia (CLL): Final Results from a Prospective Multicenter Trial (GCLLSG CLL3X study)

Peter Dreger, MD, Stephan Stilgenbauer, MD, PhD, Sebastian Boettcher, MD, Matthias Ritgen, Sascha Dietrich, Donald Bunjes, MD, Dietrich Wilhelm Beelen, MD, Sandra Cohen, MD, FRCP(C), Ute Hegenbart, Joerg Schubert, MD, Michael Stadler, MD, Bertram Glass, MD, PhD, Andreas Burchert, MD, Lutz Uharek, Michael Hallek, Michael Kneba, MD, PhD, Norbert Schmitz, MD, Hartmut Döhner

Blood (2008) 112 (11): 565.

https://doi.org/10.1182/blood.V112.11.565.565

Published: 2008

NARROW

The Addition of Ibritumomab Tiuxetan (IT) to the ATG/TLI Preparative Regimen Is Safe and May Enhance Post-Transplant Response and Outcomes for Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Health Care Utilization in Transplanted Versus Non-Transplanted Sickle Cell Disease Patients

To Evaluate the Inhibition Leukemia Cell Effect of Haploidentical Spleen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation

Bortezomib Consolidation after Nonmyeloablative Allogeneic Stem Cell Transplantation Leads to a High Incidence of Immunophenotypic Complete Response in Young and/or High-Risk Multiple Myeloma Patients

Assessment of Erythroid Chimerism in Sickle Cell Patients Undergoing HSCT By Digital Droplet PCR

Assessment Of The Endocrine Function Of Patients With Sickle Cell Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Thalidomide, Lenalidomide and Pomalidomide Disrupt Epstein-Barr Virus (EBV) Latency: Clinical Implications

Whole Genome Sequencing On Donor Cell Leukemia in a Patient with Multiple Myeloma Identified Gene Mutations That May Provide Insights to Leukemogenesis.

Improved Clinical Outcomes in Chronic Lymphocytic Leukemia Patients with 17p Deletion (CLL 17p-) Who Are Able to Proceed with a Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) Following an Initial Consultation with the Transplant Service: A Single Centre Experience

Bortezomib and BEAM-Rituximab Reduced-Intensity Conditioning for High-Risk Lymphoma Patients Who Are Not Eligible for Nonmyeloablative Allogeneic Stem Cell Transplantation

Nonmyeloablative allogeneic transplantation with or without 90 yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results

Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) for Patients with Severe Sickle Cell Disease (SCD)

Alemtuzumab Use and Survival After Reduced Intensity Allogeneic Stem Cell Transplantation in High-Risk Chronic Lymphocytic Leukemia (CLL),

Nonmyeloablative Allogeneic Stem Cell Transplantation with/ or without 90 yttrium Ibritumomab Tiuxetan ( 90 YIT) Is Curative for Relapsed Follicular Lymphoma: Median 9 Year Follow-up Results

Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial

Outcome In Follicular Lymphoma (FL) Patients (pts) Relapsing After Autologous Stem Cell Transplantation (ASCT): Allografting Vs. Conventional Therapy

Treatment of Older Patients, 40 to 70 Years of Age, with Acute Lymphoblastic Leukemia According to a Chemotherapy Regimen That Includes a Novel Pre-Phase for Rapid Tumor Load Reduction. Results of the Dutch-Belgian HOVON-71 Study.

Bendamustine Is Highly Active in Heavily Pre-Treated Relapsed and Refractory Hodgkin Lymphoma and Serves as a Bridge to Allogeneic Stem Cell Transplant.

Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NMHCT) for Patients Relapsing after Autologous Stem Cell Transplantation (autoHCT) for B Cell Non-Hodgkin Lymphoma (NHL)

Prognostic Factors for Outcome of Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) in Poor-Risk Chronic Lymphocytic Leukemia (CLL): Final Results from a Prospective Multicenter Trial (GCLLSG CLL3X study)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only